Assessment of the influence of Fc-γ receptor polymorphisms on biologics' pharmacokinetics in Tunisian rheumatoid arthritis patients.
Fc-γ receptor
adalimumab
anti-drug antibody
etanercept
infliximab
rheumatoid arthritis
rituximab
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
20
12
2022
received:
24
07
2022
accepted:
28
12
2022
medline:
11
5
2023
pubmed:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
This study aims to determine whether a modification in Fc-γ receptors' (FcgRs) affinity to Fc portion, caused by single nucleotide polymorphisms such as rs1801274-R131H FcgRIIa, rs396991-F158V FcgRIIIa and NA1/NA2-FcgRIIIb, might impact clearance of therapeutic monoclonal antibodies and thus serum drug levels and the development of anti-drug antibodies. A cross sectional, multicentral and noninterventional study was conducted in Tunisian RA patients treated with rituximab (RTX), etanercept (ETA), infliximab (IFX) and adalimumab (ADL). Serum drug level (SDL) of the different biologics and ADA against them were measured. All patients were genotyped for the 3 FcgR single nucleotide polymorphisms. A total of 81 patients were included: 47 were under tumour necrosis factor inhibitors (18 ETA, 13 ADL and 16 IFX), and 34 were under RTX. Regardless of the type of biotherapy, SDL was in therapeutic range, in 35 patients (43.2%), of whom only 1 was treated with RTX. Fourteen patients (22.2%) developed ADA, but none of the patients treated with ETA had detectable ADA levels. There was no association between SDL positivity and FcgR polymorphisms. However, the high affinity FcgR2A 131 H/H receptor was statistically more prevalent in patients with detectable ADA treated with ADL, IFX and RTX (P = .018). The same result was obtained in the monoclonal antibody tumour necrosis factor inhibitor subgroup (n = 29, P = .022) as well as in patients treated only with IFX (n = 16, P = .029). Our work supports the hypothesis of an impact of FcgR single nucleotide polymorphisms on biologics' immunogenicity, particularly FcgR R131H polymorphism, but further studies with larger cohorts need to be undertaken to confirm these results.
Substances chimiques
Adalimumab
FYS6T7F842
Antibodies, Monoclonal
0
Biological Products
0
Etanercept
OP401G7OJC
Infliximab
B72HH48FLU
Rituximab
4F4X42SYQ6
Fc gamma receptor IIA
0
FCGR3A protein, human
0
FCGR3B protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1834-1843Informations de copyright
© 2023 British Pharmacological Society.
Références
Manara M, Sinigaglia L. Bone and TNF in rheumatoid arthritis: clinical implications. RMD Open. 2015;1(Suppl 1):e000065. doi:10.1136/rmdopen-2015-000065 PMID: 26557382; PMCID: PMC4632149
Alfonso-Cristancho R, Armstrong N, Arjunji R, et al. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. ClinRheumatol. 2017;36(1):25-34. doi:10.1007/s10067-016-3435-2
Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Swiss clinical quality management physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61(5):560-568. doi:10.1002/art.24463 PMID: 19405000.
Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel. 2007;10:86-96.
Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Expert Rev Gastroenterol Hepatol. 2015;9(Suppl. 1):27-34. doi:10.1586/17474124.2015.1091307
Van Muijen ME, van der Schoot LS, van den Reek J, et al. Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide. Arch Dermatol Res. 2021;314(7):687-695. doi:10.1007/s00403-021-02273-4
Atalay S, Berends SE, Groenewoud HMM, et al. Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. J Dermatolog Treat. 2022;33(5):2680-2684. doi:10.1080/09546634.2022.2043546 Epub 2022 Feb 23. PMID: 35193441.
Sfar I, Dhaouadi T, Habibi I, et al. Functional polymorphisms of PTPN22 and FcgR genes in tunisian patients with rheumatoid arthritis. ArchInst Pasteur Tunis. 2009;86(1):51-62.
Ternant D, Mulleman D, Lauféron F, et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol. 2012;73(1):55-65. doi:10.1111/j.1365-2125.2011.04050.x
Ternant D, Ducourau E, Fuzibet P, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J ClinPharmacol. 2015;79(2):286-297. doi:10.1111/bcp.12509
Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012;14(2):296-302. doi:10.1208/s12248-012-9340-y
Price G, Patel DA. Drug bioavailability. [Updated 2022 Jun 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557852
Olivares-Morales A, Hatley OJ, Turner D, Galetin A, Aarons L, Rostami-Hodjegan A. The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. Pharm Res. 2014 Mar;31(3):720-730. doi:10.1007/s11095-013-1193-2
Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100(2):354-387. doi:10.1002/jps.22276
Wolbink GJ, Aarden LA, Dijkmans B. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211-215. doi:10.1097/BOR.0b013e328329ed8b
Gorovits B. Antidrug antibody assay validation: industry survey results. AAPS J. 2009;11(1):133-138. doi:10.1208/s12248-009-9091-6
Ruiz-Argüello B, del Agua AR, Torres N, Monasterio A, Marti'nez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med. 2013;51(12):e287-e289[PubMed] [Google Scholar]. doi:10.1515/cclm-2013-0461
Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50(8):1445-1452. doi:10.1093/rheumatology/ker124
Plasencia C, Pascual-Salcedo D, Nuño L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71(12):1955-1960. doi:10.1136/annrheumdis-2011-200828
Plasencia C, Pascual-Salcedo D, García-Carazo S, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther. 2013;15(4):R79.
Plasencia C, Pascual-Salcedo D, Alcocer P, et al. The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis. 2013;72(11):1888-1890. doi:10.1136/annrheumdis-2013-203353
Ternant D, Berkane Z, Picon L, et al. Assessment of the influence of inflammation and FcgR3A genotype on infliximab pharmacokinetics and time to relapse in patients with crohn's disease. ClinPharmacokinet. 2015;54(5):551-562. doi:10.1007/s40262-014-0225-3
Moroi R, Endo K, Kinouchi Y, et al. FcgR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics. 2013;65(4):265-271. doi:10.1007/s00251-013-0679-8
Rubbert Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1. doi:10.1186/ar2666
Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. doi:10.1002/jps.20178
Schifferli JA, Taylor RP. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 1989;35(4):993-1003. doi:10.1038/ki.1989.83
Emlen W, Carl V, Burdick G. Mechanism of transfer of immune complexes from red blood cell CR1 to monocytes. ClinExpImmunol. 1992;89(1):8-17.
Kosugi I, Muro H, Shirasawa H, Ito I. Endocytosis of soluble IgG immune complex and its transport to lysosomes in hepatic sinusoidal endothelial cells. J Hepatol. 1992;16(1):106-114. doi:10.1016/S0168-8278(05)80102-3
Berkhout LC, l'Ami MJ, Krieckaert CL, et al. The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients. Rheumatology. 2019;59:kez513. doi:10.1093/rheumatology/kez513
de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(4):531-535. doi:10.1136/ard.2008.089979
Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-fc fusion protein. N Engl J Med. 1997;337(3):141-147. doi:10.1056/NEJM199707173370301
Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13(3):R105. doi:10.1186/ar3386
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. ArthritisRheum. 2006;54(12):3782-3789. doi:10.1002/art.22214
Romero Cara P, Torres Moreno D, Pedregosa J, et al. A FcgR3A polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-TNF. Int J Med Sci. 2018;15(1):10-15. doi:10.7150/ijms.22812